# A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

> **NCT05867303** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Melanoma
- Urothelial Carcinoma
- Renal Cell Carcinoma
- Non-small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Colorectal Carcinoma

## Interventions

- **DRUG:** RC198 Injection

## Key facts

- **NCT ID:** NCT05867303
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-05
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05867303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05867303, "A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05867303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*